Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.

Key Innovative Programs

Pipeline date and pdf

Pipeline Snapshot as of January 28, 2020

Download Complete Pipeline PDF

Discovery Projects
Phase 1

26
Phase 2

37
Phase 3

23
Registration

9
Total95

Compound Name	Indication	Phase	Submission Type	Compound Type
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Serogroups ABCWY meningococcal infections	Phase 2	New Molecular Entity	Vaccine
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive and non-invasive Pneumococcal infections (adult) (BREAKTHROUGH)	Phase 3	New Molecular Entity	Vaccine
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Primary clostridioides difficile infection (FAST TRACK)	Phase 3	New Molecular Entity	Vaccine
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive and non-invasive Pneumococcal infections	Phase 2	New Molecular Entity	Vaccine
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive Group B streptococcus infection	Phase 2	New Molecular Entity	Vaccine
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Respiratory Syncytial Virus Infection	Phase 2	New Molecular Entity	Vaccine
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK Inhibitor Go to clinical trial	1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.)	Phase 3	Product Enhancement	Small Molecule
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	Cancer (Biologic)	Phase 1	Product Enhancement	Biologic
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor Go to clinical trial	ER+/HER2+ Breast Cancer	Phase 3	Product Enhancement	Small Molecule
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor Go to clinical trial	Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer	Phase 3	Product Enhancement	Small Molecule
PF-06801591 + Bacillus Calmette-Guerin (BCG) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Anti-PD-1 Go to clinical trial	Non-Muscle-Invasive Bladder cancer (Biologic) Project advanced	Phase 3	New Molecular Entity	Biologic
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor Go to clinical trial	Non-metastatic High Risk Hormone Sensitive Prostate Cancer	Phase 3	Product Enhancement	Small Molecule
Braftovi (encorafinib) + Erbitux®(cetuximab) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and EGFR inhibitor Go to clinical trial	2nd or 3rd Line BRAF-mutant Metastatic Colorectal Cancer (PRIORITY REVIEW - U.S., E.U.) Project advanced	Registration	Product Enhancement	Small Molecule
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 Go to clinical trial	1st Line Urothelial Cancer (Biologic)	Phase 3	Product Enhancement	Biologic
Daurismo (glasdegib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: SMO (smoothened) antagonist Go to clinical trial	Combo w/ low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.)	Registration	New Molecular Entity	Small Molecule
PF-05280586, a potential biosimilar to Rituxan® /MabThera® (rituximab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biosimilar Business Segment: Biopharma Mechanism of Action: CD20 Antigen Antagonist Go to clinical trial	Follicular Lymphoma (Biosimilar) (E.U.)	Registration	Biosimilar	Biosimilar
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor Go to clinical trial	Early Breast Cancer in Adjuvant Setting	Phase 3	Product Enhancement	Small Molecule
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor Go to clinical trial	High Risk Early Breast Cancer	Phase 3	Product Enhancement	Small Molecule